Infertility Clinical Trial
— niPGT-A_RCTOfficial title:
Randomized Controlled Clinical Study to Assess the Benefit of Non-invasive PGT-A, by the Analysis of Spent Blastocyst Media, as a Tool for Embryo Prioritization in Infertile Patients Undergoing Assisted Reproduction.
Chromosomal aneuploidies are linked with spontaneous miscarriages and abnormal offspring in human pregnancies. In addition, some types of aneuploidies are reported to prevent implantation. Thus, there is a need to identify the embryos with highest implantation potential on in vitro fertilization (IVF) programs. Since embryo morphology and kinetics have a weak association with embryo ploidy, trophectoderm biopsy plus Next-Generation Sequencing (NGS) is becoming a very popular approach to determine the embryo chromosomal status. This technique is called Preimplantation Genetic Testing for Aneuploidy (PGT-A). Although shown to be efficient, it is invasive for the embryo, requires specific technical skills and it remains expensive. Therefore, the development of a non-invasive, rapid and cheaper method for assessing embryo ploidy status would represent a progress in the field of IVF. The non-invasive approach has been explored by some groups that analyzed the Spent Blastocyst Medium (SBM) where the embryo was incubated up to the time of transfer or freezing. In daily routine, this media is discarded after finishing the culture of the embryo. Importantly, though, this media reportedly contains traces of embryonic cell-free DNA (cfDNA) that can represent the genetic load of the embryo. On the basis of that, the hypothesis of this study is that embryo prioritization according to the analysis of the embryonic cfDNA in the SBM could improve ongoing pregnancy rate in 10 percentual points compared to standard blastocyst transfer based on morphology.
Status | Recruiting |
Enrollment | 1108 |
Est. completion date | June 2025 |
Est. primary completion date | February 2025 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 20 Years to 40 Years |
Eligibility | Inclusion Criteria: - Patients whose written informed consent approved by the Ethics Committee (EC) has been obtained, after having been duly informed of the nature of the study and voluntarily accepted to participate after being fully aware of the potential risks, benefits and any discomfort involved. - IVF patients intending to undergo deferred day 6/7 blastocyst SET for any medical indication. - All the oocytes/embryos from the cycle should follow the laboratory protocol described in the study (embryo culture and vitrification on day 6/7). - ICSI, IVF or ICSI/IVF performed in fresh own oocytes from couples not undergoing PGT-A. Note: Donor sperm is allowed. - Female age: 20-40 years, both included. Exclusion Criteria: - Assisted hatching and artificial collapse before collecting SBM samples. Note: Both procedures are allowed only after collecting the culture media sample. - A known abnormal karyotype if the couple provides it at consultation. If not, karyotype is not compulsory. - Couples planning to undergo PGT-M or PGT-SR cases will be excluded. - Surrogate pregnancy (in those countries where it is allowed). - ERA test and embryo transfer according to ERA result. - Time-lapse culture systems are not allowed after day 4 of culture. - Presence of pathologies or malformations that affect the uterine cavity such as polyps, intramural myomas = 4cm or submucosal, septum or hydrosalpinx during the patient's participation in the study. Patients suffering these pathologies before or after their inclusion in the study can participate if the pathology is corrected before performing any study procedure. - Any illness or medical condition that is unstable or which, according to medical criteria, may put at risk the patient's safety and her compliance in the study. |
Country | Name | City | State |
---|---|---|---|
Argentina | Crecer: Centro de Reproducción y Genética Humana | Mar Del Plata | Buenos Aires |
Argentina | Saresa - Reproducción Humana Asistida | Salta | |
Brazil | Nilo Frantz - Centro de Reprodução Humana | Boa Vista | Porto Alegre |
Brazil | Vida - Centro de Fertilidade | Rio De Janeiro | |
France | Hôpital Foch | Suresnes | |
Italy | Società Italiana Studi di Medicina della Riproduzione (S.I.S.M.e.R.) | Bologna | |
Italy | Centro Procreazione Assistita DEMETRA | Firenze | |
Italy | Promea S.p.A | Torino | |
Spain | Eugin Madrid | Madrid | |
Spain | Hospital Ruber Internacional | Madrid | |
United States | Boston IVF Fertility Clinic | Boston | Massachusetts |
Lead Sponsor | Collaborator |
---|---|
Igenomix |
United States, Argentina, Brazil, France, Italy, Spain,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Non-invasive analysis of the chromosomal status of the embryo | Number and structure of the embryo chromosomes | 7 days | |
Primary | Ongoing pregnancy rate | Number of ongoing pregnancies per single embryo transfer | Over 12 weeks | |
Secondary | NGS results of the SBM | Informativity rates and prioritization category of the SBM analysis results with embryo development, culture conditions and collection time | 7 days at least | |
Secondary | Non-Invasive Prenatal Testing (NIPT) | Incidence of chromosomal abnormalities in NIPT within ongoing pregnancy cases | Up to 12 weeks | |
Secondary | Clinical miscarriage rate | Number of clinical miscarriages per total number of ongoing pregnancies | Up to 6 months after the ovum pick-up | |
Secondary | Analysis of the Products of Conception (POC) | Incidence of chromosomal abnormalities in POC within miscarriage cases | Up to 20 weeks | |
Secondary | Cumulative ongoing pregnancy rate | Cumulative ongoing pregnancy rate per patient in the 6 months after the pick-up | Over 6 months after the ovum pick-up | |
Secondary | Time to get an ongoing pregnancy | Time to get an ongoing pregnancy within the 6 months after the pick-up | Up to 6 months after the ovum pick-up | |
Secondary | Live birth rate | Number of babies born per embryo transfer | Over 40 weeks | |
Secondary | Cumulative live birth rate | Cumulative live birth rate per patient in the 6 months after the pick-up | Over 6 months after the ovum pick-up | |
Secondary | Obstetrical outcomes comparison | To compare birth weight, gestational age, APGAR, type of delivery, pregnancy complications, etc. | Over 40 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03607409 -
Role of Inhibin A as Biomarker for Ovarian Response for IVF Treatment
|
||
Recruiting |
NCT02312076 -
GnRHa for Luteal Phase Support in Long GnRHa Protocol Cycles
|
Phase 4 | |
Terminated |
NCT02161861 -
Improvement of IVF Fertilization Rates, by the Cyclic Tripeptide FEE - Prospective Randomized Study
|
N/A | |
Completed |
NCT03287479 -
Comparison of a Semi-automated Closed Vitrification System (Gavi®) With a Manual Open Vitrification Sytem (Cryotop®)
|
N/A | |
Terminated |
NCT03522350 -
Randomized Trial Comparing EmbryoScope With EmbryoScope+.
|
N/A | |
Completed |
NCT04496284 -
Embryo Transfer Outcomes After Vitrification With Slush Nitrogen Compared to Liquid Nitrogen
|
N/A | |
Completed |
NCT03623659 -
pArtiaL zonA pelluciDa Removal by assisteD hatchINg of Blastocysts
|
N/A | |
Completed |
NCT03895099 -
New Ovarian Stimulation With Random Start, Use of Progestin Protocol for Oocyte Donors
|
Phase 3 | |
Active, not recruiting |
NCT04142112 -
Randomized, Standard-Controlled, Study to Evaluate the Ohana IVF Sperm Preparation Kit, SPeRtility IVF Next Generation
|
N/A | |
Completed |
NCT03152643 -
Cumulative Live Birth Rates After Cleavage-stage Versus Blastocyst-stage Embryo Transfer
|
N/A | |
Recruiting |
NCT03683771 -
Assessment of Endometrial Pattern and Sub-endometrial Vascularity in ICSI Outcome
|
||
Recruiting |
NCT03161119 -
Comparing Two Different Embryo Transfer Catheters
|
N/A | |
Completed |
NCT04108039 -
Micronized Progesterone vs Gonadotropin-releasing Hormone (GnRH) Antagonist in Freeze-all IVF Cycles.
|
N/A | |
Completed |
NCT03678571 -
Oocyte Vitrification Aided With Latrunculin A
|
N/A | |
Completed |
NCT03678610 -
Handling Medium for ICSI With Ionomycin and Latrunculin A
|
N/A | |
Completed |
NCT03678584 -
Supplementing Intracytoplasmic Sperm Injection Handling Medium With Chaetoglobosin A ( ICSI-CA)
|
N/A | |
Completed |
NCT03677492 -
Supplementing Intracytoplasmic Sperm Injection Handling Medium With Cytochalasin D ( ICSI-CD)
|
N/A | |
Completed |
NCT03678558 -
Oocyte Vitrification Aided With Cytochalasin B
|
N/A | |
Completed |
NCT03678597 -
Supplementing Intracytoplasmic Sperm Injection Handling Medium With Latrunculin B ( ICSI-LB)
|
N/A | |
Completed |
NCT03678818 -
Supplementing Intracytoplasmic Sperm Injection Handling Medium With Latrunculin A (ICSI-LA)
|
N/A |